9 / 25
SUPERVIVENCIA LIBRE DE PROGRESIÓN (SLP)
(VALORACION POR INVESTIGADOR)
Motzer RJ, et al.
Lancet Oncol.
2015;16:1473-82
Number at risk:
Lenvatinib/everolimus
Lenvatinib
Everolimus
80
100
60
40
20
0
Progression-free survival, %
0
3
6
9
12
15
18
21
24
Time, months
0
0
0
1
1
0
5
4
1
10
6
3
16
11
7
23
20
11
27
29
15
41
41
29
51
52
50
5.5
months
Median PFS, months
Lenvatinib/everolimus
14.6 (95% CI, 5.9–20.1)
Lenvatinib
7.4 (95% CI, 5.6–10.2)
Everolimus
5.5 (95% CI, 3.5–7.1)
9.1
months
extended median PFS
14.6
months
Lenvatinib/everolimus
vs
everolimus
HR=0.40 (95% CI, 0.24–0.68); P=0.0005
Lenvatinib
vs
everolimus
HR=0.61 (95% CI, 0.38–0.98); P
=
0.048